Publications
Othman T, Logan AC, Muffly L, Leonard J, Park J, Shah B, Aldoss I. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. Journal of the National Comprehensive Cancer Network : JNCCN. 2024. PMID: 39413830
Kelly L. Schoenbeck, Anand Dhruva, Albert Lee, Anand Parikshak, Catherine Choy Smith, Neil P. Shah, Chloe Evelyn Atreya. Being Present-CML: A mindfulness-based intervention for patients with chronic myeloid leukemia taking tyrosine kinase inhibitors. Journal of Clinical Oncology. 2024. PMID:
Kelly L. Schoenbeck, Anand Dhruva, Albert Lee, Anand Parikshak, Catherine Choy Smith, Neil P. Shah, Chloe Evelyn Atreya. Being Present-CML: A mindfulness-based intervention for patients with chronic myeloid leukemia taking tyrosine kinase inhibitors. Journal of Clinical Oncology. 2024. PMID:
Cui Z, Kang H, Li H, Lee ED, Lee YS, Peterson CN, Long SR, Grandis JR, Johnson DE. CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer. Head & neck. 2024. PMID: 39347568
Moore HN, Goncalves MD, Johnston AM, Mayer EL, Rugo HS, Gradishar WJ, Zylla DM, Bergenstal RM. Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care. Clinical breast cancer. 2024. PMID: 39462728
Gritti I, Wan J, Weeresekara V, Vaz JM, Tarantino G, Bryde TH, Vijay V, Kammula AV, Kattel P, Zhu S, Vu P, Chan M, Wu MJ, Gordan JD, Patra KC, Silveira VS, Manguso RT, Wein MN, Ott CJ, Qi J, Liu D, Sakamoto K, Gujral TS, Bardeesy N. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming. Cancer discovery. 2024. PMID: 39326063
Badros AZ, Foster L, Anderson LD, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2024. PMID: 39331724
Meher N, Bidkar AP, Wadhwa A, Bobba KN, Dhrona S, Dasari C, Mu C, Fong COY, Cámara JA, Ali U, Basak M, Bulkley D, Steri V, Fontaine SD, Zhu J, Oskowitz A, Aggarwal RR, Sriram R, Chou J, Wilson DM, Seo Y, Santi DV, Ashley GW, VanBrocklin HF, Flavell RR. PET Imaging Using 89Zr Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention (EPR) in Prostate Cancer. Molecular cancer therapeutics. 2024. PMID: 39331510
Meher N, Bidkar AP, Wadhwa A, Bobba KN, Dhrona S, Dasari C, Mu C, Fong COY, Cámara JA, Ali U, Basak M, Bulkley D, Steri V, Fontaine SD, Zhu J, Oskowitz A, Aggarwal RR, Sriram R, Chou J, Wilson DM, Seo Y, Santi DV, Ashley GW, VanBrocklin HF, Flavell RR. PET Imaging Using 89Zr Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention (EPR) in Prostate Cancer. Molecular cancer therapeutics. 2024. PMID: 39331510
Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell reports. Medicine. 2024. PMID: 39368479
Oppegaard KR, Conley YP, Paul S, Cooper B, Harris CS, Shin J, Morse L, Levine JD, Cartwright F, Roy R, Melisko M, Kober KM, Hammer MJ, Miaskowski C. Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways. Journal of neural transmission (Vienna, Austria : 1996). 2024. PMID: 39325169
Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 39321214
Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 39321214
Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 39321214
Chen H, Sarah L, Pucciarelli D, Mao Y, Diolaiti ME, Fujimori DG, Ashworth A. Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements. bioRxiv : the preprint server for biology. 2024. PMID: 39386707
Chen H, Gou X, Mao Y, O'Leary PC, Diolaiti ME, Ashworth A. PARP7 Inhibitors and AHR Agonists Act Synergistically Across a Wide-Range of Cancer Models. Molecular cancer therapeutics. 2024. PMID: 39313957
Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR. Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. European urology. 2024. PMID: 39317633
Buckle GC, DeBoer R, Xu MJ, Mrema A, Rubagumya F, Velloza J, Falade AS, Van Loon K. Using context-specific evidence to inform resource-stratified cancer guidelines: A call for a new approach. Cancer. 2024. PMID: 39306723
Buckle GC, DeBoer R, Xu MJ, Mrema A, Rubagumya F, Velloza J, Falade AS, Van Loon K. Using context-specific evidence to inform resource-stratified cancer guidelines: A call for a new approach. Cancer. 2024. PMID: 39306723
Buckle GC, DeBoer R, Xu MJ, Mrema A, Rubagumya F, Velloza J, Falade AS, Van Loon K. Using context-specific evidence to inform resource-stratified cancer guidelines: A call for a new approach. Cancer. 2024. PMID: 39306723